Par Drugs and Chemicals Limited

NSEI:PAR 주식 보고서

시가총액: ₹2.9b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Par Drugs and Chemicals 대차 대조표 상태

재무 상태 기준 확인 6/6

Par Drugs and Chemicals 의 총 주주 지분은 ₹856.3M 이고 총 부채는 ₹0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 ₹1.0B 및 ₹159.8M 입니다. Par Drugs and Chemicals 의 EBIT는 ₹193.8M 이며 이자보상배율은 181 입니다. ₹366.5M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

0%

부채 비율

₹0

부채

이자 보상 비율174.3x
현금₹366.54m
주식₹856.32m
총 부채₹159.79m
총 자산₹1.02b

최근 재무 상태 업데이트

업데이트 없음

Recent updates

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Apr 16
Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Apr 05
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Nov 03
Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

May 19
If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Mar 17
Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Oct 22
Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Aug 11
Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Jul 14
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Mar 31
Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Mar 05
Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Feb 06
Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Jan 10
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Dec 13
How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

재무 상태 분석

단기부채: PAR 의 단기 자산 ( ₹596.2M )이 단기 부채( ₹124.4M ).

장기 부채: PAR 의 단기 자산( ₹596.2M )이 장기 부채( ₹35.4M ).


부채 대 자본 내역 및 분석

부채 수준: PAR 부채가 없습니다.

부채 감소: PAR 는) 부채 대 자기자본 비율이 39.9% 였던 5년 전과 비교하여 부채가 없습니다.

부채 범위: PAR 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: PAR 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.


대차 대조표


건강한 기업 발견하기